Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | DARE: dara for R/R myeloma with renal impairment

Efstathios Kastritis • 16 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Daratumumab Dexamethasone
DARE

Efstathios Kastritis, MD, of the University of Athens School of Medicine, Athens, Greece, discusses the efficacy and safety of daratumumab (dara) with dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma and severe renal impairment as evaluated in the DARE study (NCT03450057). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Efstathios Kastritis

1:45
Treatment options available for patients with AL amyloidosis beyond chemotherapy & transplant
Efstathios Kastritis • 27 Sep 2023
2:14
Managing renal failure in patients with multiple myeloma
Efstathios Kastritis • 27 Sep 2023
1:04
Treatment approaches for AL amyloidosis versus ATTR amyloidosis
Efstathios Kastritis • 27 Sep 2023
1:30
AL amyloidosis: current and prospective treatments
Efstathios Kastritis • 10 Jun 2023

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals